Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Operations (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Cash from Operations for 16 consecutive years, with 279666.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 256.6% year-over-year to 279666.0, compared with a TTM value of 214886.0 through Oct 2025, up 62.08%, and an annual FY2025 reading of 214886.0, up 62.08% over the prior year.
  • Cash from Operations was 279666.0 for Q4 2025 at Pharma-Bio Serv, up from 236524.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1105853.0 in Q3 2022 and bottomed at 1185418.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 125333.6, with a median of 248307.5 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 367.68% in 2023, then plummeted 180.18% in 2024.
  • Year by year, Cash from Operations stood at 960350.0 in 2021, then tumbled by 72.92% to 260091.0 in 2022, then rose by 18.59% to 308436.0 in 2023, then crashed by 74.57% to 78425.0 in 2024, then soared by 256.6% to 279666.0 in 2025.
  • Business Quant data shows Cash from Operations for PBSV at 279666.0 in Q4 2025, 236524.0 in Q3 2025, and 301590.0 in Q2 2025.